Ensysce Biosciences, Inc (ENSC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ENSC Stock Price Chart Interactive Chart >
ENSC Price/Volume Stats
| Current price | $0.70 | 52-week high | $36.47 |
| Prev. close | $0.71 | 52-week low | $0.59 |
| Day low | $0.66 | Volume | 1,110,307 |
| Day high | $0.73 | Avg. volume | 4,723,840 |
| 50-day MA | $1.27 | Dividend yield | N/A |
| 200-day MA | $7.53 | Market Cap | 4.49M |
Ensysce Biosciences, Inc (ENSC) Company Bio
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.
Latest ENSC News From Around the Web
Below are the latest news stories about ENSYSCE BIOSCIENCES INC that investors may wish to consider to help them evaluate ENSC as an investment opportunity.
Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 StudyEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), (OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the initiation of the final stage of the Phase 1 study of PF614-MPAR. |
Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth InvitationalEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that Chief Executive Officer, Dr. Lynn Kirkpatrick, will present a company overview at the Diamond Equity Research 2023 Virtual Emerging Growth Invitational on Wednesday, January 25th, 2023, at 12:20 p.m. Eastern Time. |
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on January 25, 2023Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Emerging Growth Invitational Investor Conference on January 25, 2023. The conference, which is open to all retail and institutional investors, will consist of a series of twenty-five-m |
Ensysce Biosciences Issues 2023 Shareholder LetterEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick. |
Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential TrialEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has successfully completed the clinical portion of study PF614-104, ‘A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study to Evaluate the Oral Abuse Potential of PF614 Compared with Oxycodone |
ENSC Price Returns
| 1-mo | -6.67% |
| 3-mo | -75.35% |
| 6-mo | -92.63% |
| 1-year | -97.99% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -6.67% |
| 2022 | -99.20% |
| 2021 | -62.20% |
| 2020 | 19.33% |
| 2019 | 6.11% |
| 2018 | N/A |
Loading social stream, please wait...